Essais liés9clinical trials
VilleAlbuquerquelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT03939312

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Atogepant Migraine Phase 3 NCT03777059 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine COMPLETED
Atogepant Migraine Phase 3 NCT03939312 Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine COMPLETED
Dihydroergotamine Migraine Phase 3 NCT03901482 EMERGE — A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine COMPLETED
Dihydroergotamine Migraine Phase 3 NCT04406649 ASCEND — A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine COMPLETED
Dihydroergotamine Migraine Phase 3 NCT04940390 SUMMIT — A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine COMPLETED
Elismetrep Migraine Phase 3 NCT07645924 A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine RECRUITING
Elismetrep Migraine Phase 3 NCT07674654 A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine RECRUITING
MEDI0618 Migraine Phase 2 NCT06602479 AURORA — A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine ACTIVE_NOT_RECRUITING
Galcanezumab Migraine Phase 3 NCT02614261 REGAIN — Evaluation of Galcanezumab in the Prevention of Chronic Migraine COMPLETED